Keyphrases
Tumor Necrosis Factor-α
100%
Crohn's Disease
100%
Cytokine Receptor
100%
Infliximab
100%
Treatment Failure
100%
Circulating Cytokines
100%
Interleukin-6
54%
Non-immune
36%
Pharmacokinetics
36%
Pharmacodynamics
27%
Inflammatory Response
18%
Non-responders
18%
Anti-infliximab Antibodies
18%
Infliximab Failure
18%
Remission
18%
Interleukin-1β
18%
Treatment Intensification
9%
Enzyme-linked Immunosorbent Assay (ELISA)
9%
Cell-based
9%
Disease Activity
9%
Infliximab Levels
9%
Monocyte Chemoattractant protein-1 (MCP-1)
9%
Clinical Trials
9%
Clinical Response
9%
Interleukin-17 (IL-17)
9%
Long-term Remission
9%
Signaling Pathway
9%
Interleukin-10
9%
Interleukin-1Ra
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Interleukin-12p70
9%
Nontumor
9%
TNF Receptor 1 (TNFR1)
9%
Interferon-γ
9%
Reporter Gene Assay
9%
Immunology and Microbiology
Infliximab
100%
Cytokine
100%
Tumor Necrosis Factor
100%
Cytokine Receptor
100%
Crohn's Disease
100%
Interleukin 6
37%
Pharmacokinetic
25%
Pharmacodynamics
18%
Interleukin 1
12%
Inflammation Response
12%
Tumor Necrosis Factor Alpha
6%
Granulocyte Macrophage Colony-Stimulating Factor
6%
Monocyte Chemotactic Protein 1
6%
Interleukin 17
6%
Interleukin 10
6%
Interferon
6%
Interleukin 12p70
6%
Enzyme-Linked Immunosorbent Assay
6%
Population Research
6%
Reporter Gene
6%
Tumor Necrosis Factor Receptor 1
6%
Veterinary Science and Veterinary Medicine
Neoplasm
100%
Granulocyte Macrophage Colony-Stimulating Factor
16%